The drug distributor’s pharmaceutical segment in the U.S. is its largest unit by revenue that sells drugs used to treat complex conditions such as cancer and the segment recorded a 7 per cent rise in first-quarter revenue to $71.7 billion, but fell short of analysts’ expectations of $74.1 billion. The Texas-headquartered company raised its fiscal 2025 adjusted per-share profit to between $31.75 and $32.55 compared to its previous forecast of $31.25 to $32.05 per share.
News
McKesson misses quarterly revenue as U.S. pharmaceutical segment weighs
August 9, 2024The drug distributor’s pharmaceutical segment in the U.S. is its largest unit by revenue that sells drugs used to treat complex conditions such as cancer and the segment recorded a 7 per cent rise in first-quarter revenue to $71.7 billion, but fell short of analysts’ expectations of $74.1 billion. The Texas-headquartered company raised its fiscal 2025 adjusted per-share profit to between $31.75 and $32.55 compared to its previous forecast of $31.25 to $32.05 per share.